Novel genetic techniques and approaches in the microbial genomics era: Identification and/or validation of targets for the discovery of new antibacterial agents

Drugs in R and D

Volumn 8, Issue 4, 2007, Pages 201-212

  Pucci, Michael J ^a  

^a Achillion Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BENZOIC ACID DERIVATIVE; BENZOYLAMINOBENZOIC ACID; COMPLEMENTARY RNA; DNA TOPOISOMERASE (ATP HYDROLYSING) B; PEPTIDE DEFORMYLASE INHIBITOR; PLATENSIMYCIN; PROTEIN INHIBITOR; PROTEIN PARE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BACTERIAL STRAIN; BIOINFORMATICS; DNA MICROARRAY; DNA MODIFICATION; DNA RESTRICTION; DNA SEQUENCE; DRUG INDUSTRY; DRUG TARGETING; ENERGY METABOLISM; ESCHERICHIA COLI; GENE EXPRESSION PROFILING; GENETIC IDENTIFICATION; GENETIC PROCEDURES; HELICOBACTER PYLORI; MICROBIAL GENETICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OPEN READING FRAME; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; DRUG EVALUATION, PRECLINICAL; GENOME, BACTERIAL; GENOMICS; HUMANS; MODELS, THEORETICAL; TECHNOLOGY, PHARMACEUTICAL;

EID: 34347387986     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708040-00001     Document Type: Review

References (101)

1. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999 Jan 6; 281 (1): 61-6
2. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003; 36 Suppl.: S11-23
3. Levy SB, Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004; 10 (12 Suppl.): S122-9
4. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6 (5): 427-30
5. IDSA Report: Bad bugs, no drugs, as antibiotic discovery stag nates, a public health crisis brews: July 2004 [online]. Available from URL: http://www.idsociety.org [Accessed 2007 Jun 13 ]
6. Barrett CT, Barrett JF. Antibacterials: are the new entries enough to deal with the emerging resistance problems? Curr Opin Biotechnol 2003; 14 (6): 621-5
7. Fleischmann RD, Adams MD, White O, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995; 269 (5223): 496-512
8. Marguiles M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005; 437 (7057): 376-80
9. Fox JA, Butland SL, McMillan, et al. The Bioinformatics Links Directory: a compilation of molecular biology web servers. Nucleic Acids Res 2006; 34 (Web Server issue): W3-W24
10. Dharmadi Y, Gonzalez R. DNA microarrays: experimental issues, data analysis, and application to bacterial systems. Biotechnol Prog 2004; 20: 1309-24
11. Bandow JE, Brotz H, Leichert LI, et al. Proteomic approach to understanding antibiotic drug discovery. Antimicrob Agents Chemother 2003; 47 (3): 948-55
12. Barker JJ. Antibacterial drug discovery and structure-based design. Drug Discov Today 2006; 11 (9-10): 391-404
13. Clardy J, Fischbach MA, Walsh CT. New antibiotics from bacterial natural products. Nat Biotechnol 2006; 24 (12): 1541-50
14. Marra A. Targeting virulence for antibacterial chemotherapy. Drugs R D 2006; 7 (1): 1-16
15. Mazurkiewicz P, Tang CM, Boone C, et al. Signature-tagged mutagenesis: barcoding mutants for genome-wide screens. Nature Rev Genet 2006; 7 (12): 929-39
16. Raskin DM, Seshadri R, Pukatzki SU, et al. Bacterial genomics and pathogen evolution. Cell 2006; 124: 703-14
17. Web Server Issue. Nucleic Acids Res 2006; 34: W1-W752
18. Chen YB, Chattopadhyay A, Bergen P, et al. The online bioinformatics resources collection at the University of Pittburgh Health Sciences Library System: a one-step gateway to online bioinformatics databases and software tools. Nucleic Acids Res 2007; 35: D780-5
19. Altschul SF, Madden TL, Schäffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25 (17): 3389-402
20. Chenna R, Sugawara H, Koike T, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003; 31 (13): 3497-500
21. Morgenstern B, Frech K, Dress A, et al. DIALIGN: finding local similarities by multiple sequence alignment. Bioinformatics 1998; 14 (3): 290-4
22. Brudno M, Do CB, Cooper GM, et al. LAGAN and Multi-LAGAN: efficient tools for large-scale multiple alignment of genomic DNA. Genome Res 2003; 13 (4): 721-31
23. Bruccoleri RE, Dougherty TJ, Davison DB. Concordance analysis of microbial genomes. Nucleic Acids Res 1998; 26 (19): 4482-6
24. Dessimoz C, Boeckmann B, Roth AC, et al. Detecting non-orthology in the COGs database and other approaches grouping orthologs using genome-specific best hits. Nucleic Acids Res 2006; 34 (11): 3309-16
25. Caspi R, Foerster H, Fulcher CA, et al. Meta Cyc: a multiorganism database of metabolic pathway enzymes. Nucleic Acids Res 2006; 34 (Database issue): D511-6
26. EcoCyc Kessler IM, Collado-Vides J, Gama-Castro S. EcoCyc: a comprehensive database resource for Escherichia coli. Nucleic Acids Res 2005; 33 (Database issue): D334-7
27. Zhang R, Zhang C-T. The impact of comparative genomics on infectious disease research. Microbes Infect 2006; 8 (6): 1613-22
28. Alm RA, Ling LS, Moir DT, et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999; 397 (6715): 176-80
29. Hayashi T, Makino K, Ohnishi M, et al. Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res 2001; 8 (1): 11-22
30. Perna NT, Plunkett 3rd G, Burland V, et al. Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature 2001; 409 (6819): 529-33
31. Mau B, Glasner JD, Darling AE, et al. Genome-wide detection and analysis of homologous recombination among sequenced stains of Escherichia coli. Genome Biol 2006; 7 (5): R44
32. Lindsay JA, Holden MT. Understanding the rise of the superbug: investigation of the evolution and genomic variation of Staphylococcus aureus. Funct Integr Genomics 2006; 6 (3): 186-201
33. Holden MT, Feil RJ, Lindsay JA, et al. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci U S A 2004; 101 (26): 9786-91
34. Gill SR, Fouts DE, Archer GL, et al. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain. J Bacteriol 2005; 187 (7): 2426-38
35. Marri PR, Bannantine JP, Golding GB. Comparative genomics of metabolic pathways in Mycobacterium species: gene duplication, gene decay and lateral gene transfer. FEMS Microbiol Rev 2006; 30 (6): 906-25
36. Hain T, Steinweg C, Chakraborty T. Comparative and functional genomics of Listeria spp. J Biotechnol 2006; 126 (1): 37-51
37. Hotopp JC, Lin M, Madupu R, et al. Comparative genomics of emerging human ehrlichiosis agents. PLoS Genet 2006; 2 (2): e21
38. Parkhill J, Sebaihia A, Preston A, et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 2003; 35 (1): 32-40
39. Rasko DA, Altherr MR, Han CS, et al. Genomics of the Bacillus cereus group of organisms. FEMS Microbiol Rev 2005; 29 (2): 303-29
40. Anderson I, Sorokin A, Kapatrol V, et al. Comparative genome analysis of Bacillus cereus group genomes with Bacillus subtilis. FEMS Microbiol Lett 2005; 250 (2): 175-84
41. Payne DJ, Gywnn MN, Holmes DJ, et al. Drugs for bad drugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6 (1): 29-40
42. Pucci MJ, Dougherty TD. Use of genomics to select antibacterial targets. Biochem Pharmacol 2006; 71 (7): 1066-72
43. Glass JI, Assad-Garcia N, Alperovich N, et al. Essential genes of a minimal bacterium. Proc Natl Acad Sci U S A 2006; 103 (2): 425-30
44. Freiberg C, Brotz-Oesterhelt H. Functional genomics in antibacterial drug discovery. Drug Discov Today 10 (13): 927-935
45. Thanassi JA, Hartman-Neumann SL, Dougherty TJ, et al. Identification of 113 conserved essential genes using a high-throughput gene disruption system in Streptococcus pneumoniae. Nucleic Acids Res 2002; 30: 3152-62
46. Gerdes SY, Scholle MD, Campbell JW, et al. Experimental determination and system level analysis of essential genes in Escherichia coli MG1655. J Bacteriol 2003; 185 (19): 5673-84
47. Akerley BJ, Rubin EJ, Novick VL, et al. A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proc Natl Acad Sci U S A 2002; 99 (2): 966-71
48. Forsyth RA, Haselbeck RJ, Ohlsen KL, et al. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol Microbiol 2002; 43 (6): 1387-400
49. Ji Y, Zhang B, Van SF, et al. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 2001; 293 (5538): 2266-9
50. DeVito JA, Mills JA, Liu VG, et al. An array of target-specific screening strains for antibacterial discovery. Nat Biotechnol 2002 May; 20 (5): 478-83
51. Zhang L, Fan F, Palmer LM, et al. Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action. Gene 2000; 255 (2): 297-305
52. Huang J, O'Toole PW, Shen W, et al. Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48 (3): 909-17
53. Badger J, Sauder JM, Adams JM, et al. Structural analysis of a set of proteins resulting from a bacterial genomics project. Proteins: Struct Funct Bioinform 2005; 60: 787-96
54. Fogg MJ, Alzari P, Bahar M, et al. Application of the use of high-throughput technologies to the determination of protein structures of bacterial and viral pathogens. Acta Crystallogr D Biol Crystallogr 2006; 62 (Pt 10): 1196-207
55. Au K, Berrow NS, Blagova E, et al. Application of high-throughput technologies to a structural proteomics-type analysis of Bacillus anthracis. Acta Crystallogr D Biol Crystallogr 2006; 62 (Pt 10): 1267-75
56. Su XD, Liang Y, Li L, et al. A large-scale, high-efficiency and low-cost platform for structural genomics studies. Acta Crystallogr D Biol Crystallogr 2006; 62 (Pt 8): 843-51
57. Hermann T. Drugs targeting the ribosome. Curr Opin Struct Biol 2005; 15 (3): 355-66
58. Sutcliffe JA. Improving on nature: antibiotics that target the ribosome. Curr Opin Microbiol 2005; 8 (5): 534-42
59. Franceschi F, Duffy EM. Structure-based drug design meets the ribosome. Biochem Pharmacol 2006; 71 (7): 1016-25
60. Grossman TH, Bartels DJ, Mullin S, et al. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother 2007; 51 (2): 657-66
61. Howard MH, Cenizal T, Gutteridge S, et al. A novel class of inhibitors of peptide deformylase discovered through high-concentrations throughput screening and virtual ligand screening. J Med Chem 2004; 47 (27): 6669-72
62. Nie Z, Perretta C, Lu J, et al. Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. J Med Chem 2005; 48 (5): 1596-609
63. Wang J, Soisson SM, Young K, et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006; 441 (7091): 358-61
64. Seefeld MA, Miller WH, Newlander KA, et al. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J Med Chem 2003; 46 (9): 1627-35
65. Reck F, Zhou F, Giradot M, et al. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem 2005; 48 (2): 499-506
66. Depristo MA, deBakker PI, Blundell TL. Heterogeneity and inaccuracy in protein structures solved by x-ray crystallography. Structure 2004; 12 (5): 831-8
67. Erlanson DA, McDowell RS, O'Brien T. Fragment based drug discovery. J Med Chem 2004; 47 (14): 3463-82
68. Shuker SB, Hadjuk PJ, Meadows RP, et al. Discovering high-coming affinity ligands for proteins: SAR by NMR. Science 1996; 274 (5292): 1531-4
69. Tsao DH, Sutherland AG, Jennings LD, et al. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. Bioorg Med Chem 2006; 14 (23): 7953-61
70. Chen D, Yuan Z. Therapeutic potential of peptide deformylase inhibitors. Expert Opin Investig Drugs 2005; 14 (9): 1107-16
71. Freiberg C, Brotz-Oesterhelt H. Functional genomics in antibacterial drug discovery. Drug Discov Today 2005; 10 (13): 927-35
72. Conway T, Schoolnik GK. Microarray expression profiling: capturing a genome-wide portrait of the transcriptome. Mol Microbiol 2003; 47 (4): 879-89
73. Schoolnik GK. Microarray analysis of bacterial pathogenicity. Adv Microb Physiol 2002; 46: 1-45
74. Petersohn A, Brigulla M, Haas S. Global analysis of the general stress response of Bacillus subtilis. J Bacteriol 2001; 183 (19): 5617-31
75. Van Bogelen RA, Schiller EE, Thomas JD, et al. Diagnosis of cellular states of microbial organisms using proteomics. Electrophoresis 1999; 20 (11): 2149-59
76. Han MJ, Lee SY. The Escherichia coli proteome: past, present, and future prospects. Microbiol Mol Biol Rev 2006; 70 (2): 362-439
77. Hecker M, Volker U. Towards a comprehensive understanding of Bacillus subtilis cell physiology by physiological proteomics. Proteomics 2004; 4 (12): 3727-50
78. Mawuenyega KG, Forst CV, Dobos KM, et al. Mycobacterium tuberculosis functional network analysis by global subcellular protein profiling. Mol Biol Cell 2005; 16 (1): 396-404
79. Brazas MD, Hancock RE. Using microarray gene signatures to elucidate mechanisms of antibiotic action and resistance. Drug Discov Today 2005; 10 (18): 1245-52
80. Ng WL, Kazmierczak KM, Robertson GT. Transcriptional regulation and signature patterns revealed by microarray analyses of Streptococcus pneumoniae R6 challenged with sublethal concentrations of translation inhibitors. J Bacteriol 2003; 185 (1): 359-70
81. Lin JT, Connelly MB, Amolo C, et al. Global transcriptional response of Bacillus subtilis to treatment with subinhibitory concentrations of antibiotics that inhibit protein synthesis. Antimicrob Agents Chemother 2005; 49 (5): 1915-26
82. Freiberg C, Fischer HP, Brunner NA. Discovering the mechanism of action of novel antibacterial agents through transcriptional profiling of conditional mutants. Antimicrob Agents Chemother 2005; 49 (2): 749-59
83. Fraser CM, Rappouli R. Application of microbial genomic science to advanced therapeutics. Annu Rev Med 2005; 56: 459-74
84. Boshoff HIM, Manjunatha UH. The impact of genomics on discovering drugs against infectious diseases. Microbes Infect 2006; 8: 1654-61
85. Chen D, Yuan Z. Therapeutic potential of peptide deformylase inhibitors. Expert Opin Investig Drugs 2005; 14 (9): 1107-16
86. Chan PF, Holmes DJ, Payne DJ. Finding the gems using genomic discovery: antibacterial drug discovery strategies: the successes and the challenges. Drug Discov Today: Ther Strategies 2004; 1 (4): 519-27
87. Dougherty TJ, Miller PF. Microbial genomics and drug discovery: exploring innovative routes of drug discovery in the postgenomic era. IDrugs 2006; 9 (6): 420-2
88. Black MT, Hodgson J. Novel target sites in bacteria for overcoming antibiotic resistance. Adv Drug Deliv Rev 2005; 57: 1528-38
89. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 2004; 64 (2): 159-204
90. Darvas F, Gorman G, Krajcsi P, et al. Recent advances in chemical genomics. Curr Med Chem 2004; 11 (23): 3119-45
91. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46 (1-3): 3-26
92. Singh SB, Barrett JF. Empirical antibacterial drug discovery: foundation in natural products. Biochem Pharmacol 2006; 71 (7): 1006-15
93. Young K, Jayasuriya H, Ondeyka JG, et al. Discovery of FabH/FabF inhibitors from natural products. Antimicrob Agents Chemother 2006; 50 (2): 519-26
94. Christoffersen RE. Antibiotics: an investment worth making? Nat Biotechnol 2006; 24 (12): 1512-4
95. Fox JL. The business of developing antibacterials. Nat Biotechnol 2006; 24 (12): 1521-8
96. Fernandes P. Antibacterial discovery and development: the failure of success? Nat Biotechnol 2006; 24 (12): 1497-503
97. Becker D, Selbach M, Rollenhagen C, et al. Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature 2006; 440: 303-7
98. Leeds JA, Schmitt EK, Krastel P. Recent developments in antibacterial drug discovery: microbe-derived natural products: from collection to the clinic. Expert Opin Investig Drugs 2006; 15 (3): 211-26
99. Shoichet BK. Virtual screening of chemical libraries. Nature 2004; 432: 862-5
100. Congreve M, Murray CW, Blundell TL. Structural biology and drug discovery. Drug Discov Today 2005; 10 (13): 895-907
101. Vicente M, Hodgson J, Massidda O, et al. The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? FEMS Microbiol Rev 2006; 30: 841-52